Cryoport reports third quarter 2024 financial results

Q3 2024 life sciences services revenue up 9% year-over-year, including biostorage/bioservices revenue up 12% year-over-year supported a record total of 691 global clinical trials as of september 30, 2024 company reaffirmed full year 2024 revenue guidance of $225 to $235 million nashville, tenn. , nov. 7, 2024 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) (cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (q3) and first nine months (9m) of 2024.
CYRX Ratings Summary
CYRX Quant Ranking